Judith Hsia, MD, a Non-invasive Cardiologist, Lipidologist and Research Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine, as well as Chief Science Officer at CPC. Dr. Hsia earned her medical degree from the University of Illinois School of Medicine and completed her internship and residency in Internal Medicine at Tufts-New England Medical Center. She served as a Research Associate at the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), and Cardiology Fellow at George Washington University.
After completion of her training, Dr. Hsia joined the faculty as an Assistant Professor of Medicine in the Division of Cardiology at George Washington University, with subsequent promotion to Associate and Full Professor. She was an active member of the non-invasive cardiology labs at George Washington University and director of the outpatient Vascular Laboratory and Lipid Research Clinic. In addition, she was principal investigator for an NHLBI-funded RO1 focused on human immunodeficiency virus-related heart disease. She was also principal investigator for the NIH-funded Women’s Health Initiative (WHI), which demonstrated the effects of post-menopausal hormone therapy on cardiovascular disease, cancer and fracture risk, of low-fat diet for cancer and heart disease prevention and of calcium and vitamin D supplementation on fracture. For the WHI, she served on the Executive Committee and co-chaired the Outcomes Adjudication Committee. She also chaired the Endpoint Adjudication Committees for 2 other NIH multicenter trials, the Women’s Angiographic Vitamin and Estrogen (WAVE) trial and the Prevention of Events with ACE inhibition (PEACE) trial and served on Data Safety Monitoring Committees for 3 NIH multicenter trials, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) and Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy (REBIRTH), chairing the latter two studies.
Most recently, Dr. Hsia spent 12 years at AstraZeneca leading cross-functional product development teams for cardiovascular and renal biologic drugs and as global clinical lead for LOKELMA®, roxadustat and BRILINTA® with responsibility for global clinical strategy development and implementation, clinical regulatory and commercial support. She was the study physician for the JUPITER trial, leading the early closeout and rapid reporting of that study which demonstrated CV event reduction with Crestor® in patients without established cardiovascular disease. Her current interests include advancing pragmatic trial methodologies in clinical trials for cardiovascular and renal diseases.